Objective To analyze the trends and changes in the burden of chronic kidney dis-ease(CKD)in China from 1990 to 2021.Methods Data related to the burden of CKD in China from the 2021 Global Burden of Disease(GBD)Study public database were downloaded.Descriptive analyses were conducted using indicators such as age-standardized incidence rates,mortality rates,years of life lost(YLL)rates,years lived with disability(YLD)rates,and disability-adjusted life years(DALY)rates.The Joinpoint regression model was employed to analyze the trends in CKD.The Nordpred model was used to predict the standardized mortality rates,prevalence rates,and inci-dence rates of CKD in China over the next 20 years.Results The age-standardized incidence rate of CKD in China increased from 147.29 per 100,000 in 1990 to 163.74 per 100,000 in 2021,while the age-standardized prevalence rates,mortality rates,YLL rates,YLD rates,and DALY rates all ex-hibited downward trends.The incidence and prevalence of CKD were higher in Chinese women than in men,while mortality rates and DALY rates were lower in women than in men.The burden of CKD increased with age.It is estimated that by 2045,the incidence and prevalence of CKD in China will continue to rise,but the standardized mortality rate and standardized prevalence rate will decline.Conclusion Based on the current status and trends in the burden of CKD in China,implementing precise health management for different populations can help reduce the burden of CKD in China.

Objective To explore the effect and associated mechanism of fluvastatin combined with losartan on the expression of vascular endothelial growth factor (VEGF) in human podocytes induced by angiotensin (Ang)Ⅱ.Methods The differentiated human podocytes were cultured with various concentrations of Ang Ⅱ (10-9 to 10-5 mol/L) in vitro,followed by treatment of fluvastatin (10-7,10-6 and 10-5 mol/L),losartan (10-7,10-6 and 10-5 mol/L),extracellular signal-regulated kinase (ERK) inhibitor PD98059,and combination of fluvastatin and lolsartan.Expressions of VEGF and phosphorylation (p)ERK1/2 protein in podocytes were detected by Western blotting.RT-PCR was used to examine VEGF mRNA expression (P＜0.01).Results Ang Ⅱ up-regulated the expressions of VEGF and p-ERK1/2 in time-and dose-dependent manner.Above elevated expressions of VEGF and p-ERK1/2 induced by Ang Ⅱ could be down-regulated by fluvastatin,losartan and PD98059 respectively (P＜0.05).More obvious reduction of above expressions was found in combination of fluvastatin and losartan as compared to single agent (P ＜0.05).Conclusions Either fluvastatin or losartan can down-regulate the over-expression of VEGF and p-ERK1/2 induced by Ang Ⅱ in human podocytes,and their combination has a cooperative effect.The ERK signaling pathway may be one of the mechanisms of their renal protective effects.